Advertisement
Advertisement
U.S. markets close in 3 hours 47 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Eterna Therapeutics Inc. (ERNA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
5.18+0.28 (+5.71%)
As of 12:12PM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Bollinger Bands

Bollinger Bands

Previous Close4.90
Open4.77
Bid5.20 x 1000
Ask5.28 x 900
Day's Range4.64 - 5.35
52 Week Range2.74 - 116.20
Volume87,403
Avg. Volume135,572
Market Cap26.558M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ERNA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Eterna Therapeutics Inc.
    MTCH: Lowering target price to $45.00MATCH GROUP INC has an Investment Rating of HOLD; a target price of $45.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    2 days agoArgus Research
View more
  • GlobeNewswire

    Eterna Therapeutics Announces Research Collaboration to Develop Advanced Gene-Edited iPS Cell Therapies

    SAN DIEGO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a biopharmaceutical company using advanced cell engineering technology to develop transformational new medicines, today announced it has entered into a sponsored research agreement with Michael Andreeff, M.D., Ph.D., Professor of Leukemia at The University of Texas MD Anderson Cancer Center (“MD Anderson”). Under the agreement, Dr. Andreeff will evaluate the capacity of Eterna’s gene

  • GlobeNewswire

    Eterna Therapeutics to Present at iPSC-Derived Immunotherapies Congress

    SAN DIEGO, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a biopharmaceutical company using advanced cell engineering technology to develop transformational new medicines, today announced that Matt Angel, Ph.D., Interim Chief Executive Officer of Eterna, will present at the iPSC-Derived Immunotherapies Congress, taking place October 18-19, 2022 in Boston. Details of Presentation Title: Avoiding Vector Integration Using mRNA Vectorization of

  • GlobeNewswire

    Eterna Therapeutics Completes Name Change, Acquires Option to License iPSC-Derived NK and T Cell Therapies from Exacis Biotherapeutics

    The Eterna corporate mission is to realize the potential of cell engineering to provide patients with transformational new medicines Exacis’ iNK and iT cells, made using non-viral, episome-free cell engineering technology, include advanced ‘stealthing’ edits, and can target virtually any cancer antigen SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a biopharmaceutical company using advanced cell engineering technology to develop

Advertisement
Advertisement